Turning Biomarker Insight into Clinical Action

Therapy Area:

Oncology & Hematology

Product Stage:

Post-launch

Company Type:

Top 10 global pharmaceutical company

Location:

North America & Asia-Pacific

The challenge

In hematological malignancies, timely action on biomarkers associated with poor prognosis can significantly influence outcomes. Yet when a biomarker is rare and newly actionable, gaps in awareness and visibility can delay clinical decisions.

In this case study, biomarker results were often overlooked or not recalled at the point of care, and traditional field-based outreach was not possible in zero-access settings. When education is delivered too late in the care pathway, opportunities to influence decisions may be missed, with direct implications for patients.

The result was clinical hesitation at the moment it mattered most in the care pathway.

Our Approach

To address these challenges, Diaceutics deployed Expert Exchange, a real-time, peer-to-peer education model designed to support clinical decision-making.

Rather than delivering broad education in advance, the program was triggered by active diagnostic signals, ensuring relevance and immediacy. Expert engagement was initiated within 48 hours of an actionable result, while cases were still under active consideration.

The program delivered:

Non‑promotional, expert‑led conversations grounded in real patient scenarios
Peer discussion tailored to the specific biomarker, disease context, and clinical questions
Targeted outreach informed by real-world diagnostic data, not blanket HCP lists
Access to clinicians in restricted and low‑coverage institutions, where traditional engagement was not possible

The impact

By aligning expert insight with real diagnostic results, Expert Exchange helped turn diagnostic signals into action, supported multidisciplinary collaboration, and reduced the risk that patients would be disadvantaged by gaps in access or awareness.

The Expert Exchange program delivered clear early results across engagement, awareness, and clinical action.

75% HCP engagement achieved within the first month
Sustained relevance driven by ongoing weekly patient signals
More than 20% increase in accessibility for zero- and restricted-access accounts through the program

Learn more

We’ve been with pharma and biotech companies for over 20 years, helping them to make more informed diagnostic and therapeutic decisions based on real-world data. Our platforms and tools provide global insight from a network of laboratories across 50+ countries.

This unparalleled visibility into real-world testing helps support therapy programs across oncology, cardiology, neurology, autoimmune, rare diseases, and many more.

Newsletter sign up

Sign up to our bi-weekly newsletter covering the latest insights to optimize commercialization of diagnostic driven therapies to help empower your decisions.

READY TO DO COMMERCIALIZATION DIFFERENTLY?

Every patient journey contains opportunities to improve testing, engagement, and adoption. We can help you find them so more people get the right therapy sooner.

TALK TO US